FDA drafts premarket testing recommendations for robotic surgery systems

The Food and Drug Administration has issued draft guidance spelling out what it expects to see in premarket submissions for surgical robots. The agency announced the availability of the document, titled "Robotically-Assisted Surgical Devices—Premarket Submissions," in the Federal Register on 25 September 2026, and is taking comment until 24 November 2026 [s1].

The guidance is a draft. It is "not final nor is it for implementation at this time," and when finalised it will represent the agency's current thinking rather than binding law [s1]. It is being issued under the FDA's good guidance practices regulation at 21 CFR 10.115, which means it does not establish rights for any party and that manufacturers may use an alternative approach if it meets the applicable statutes and regulations [s1]. The document and its docket, numbered FDA-2026-N-9505, are available for review and comment on the federal rulemaking portal [s2].

What the guidance covers

The FDA describes robotically-assisted surgical devices, or RASDs, as teleoperated, software-controlled systems that integrate robotic technologies and subassemblies and are designed to help qualified practitioners precisely position and control multiple surgical instruments, in order to perform open, minimally invasive or endoluminal procedures safely and effectively [s1]. These are the platforms a surgeon operates from a console to drive instruments inside a patient.

The draft provides recommendations on the non-clinical and clinical testing and on the premarket submission content the agency expects for these devices [s1]. The agency says the recommendations reflect its current thinking and are intended to promote consistency and to make its review of premarket submissions more efficient [s1]. In other words, the document aims to tell manufacturers up front what evidence a robotic-surgery submission should contain, rather than leaving each company to infer it.

Where it fits in device law

The guidance does not create a new approval route; it sits on top of the existing pathways the FDA uses for devices, which the notice references through the records those submissions rely on [s1]. Depending on a device's risk and novelty, a robotic-surgery system may reach the market through premarket notification — the 510(k) route under 21 CFR part 807 — through premarket approval under part 814, or through De Novo classification under part 860, subpart D [s1]. Clinical study of an investigational device is governed by the Investigational Device Exemption rules in part 812, and marketed devices remain subject to labelling and unique-device-identification requirements, the quality management system regulation in part 820, and postmarket surveillance under part 822 [s1]. Studies that support a submission are also bound by the human-subject protection and institutional-review-board rules in parts 50 and 56 and, for laboratory work, the good laboratory practice regulation in part 58 [s1].

By consolidating its expectations into a single document, the agency is attempting to standardise how the growing field of surgical robotics is evaluated before devices reach operating rooms. The notice says the guidance contains no new collection of information, instead referring to previously approved paperwork requirements [s1].

A deliberately open process

The timing matters for manufacturers and hospitals weighing investments in these systems. Because the guidance is still in draft, the recommendations could change before they are finalised, and the agency has explicitly invited input. The FDA says it will consider comments on the costs or cost savings the guidance may generate, a consideration tied to Executive Order 14192 [s1]. Comments must be submitted by 24 November 2026 to be assured of consideration before the agency begins work on the final version [s1].

What is settled and what is not

What is fixed is modest but concrete: a dated draft guidance now exists, a public docket is open, and the agency has defined what a robotically-assisted surgical device is for the purposes of its review [s1][s2]. The core regulatory fact is that these systems are, and remain, medical devices subject to premarket review; the guidance clarifies the evidence expected within that framework rather than changing the framework itself [s1].

What is not yet settled is the substance of the final recommendations. A draft guidance is a proposal, and the specific testing expectations can be revised, narrowed or expanded in response to comment before the FDA finalises them [s1]. Until then, the document functions as a signal of the agency's direction on surgical robotics — authoritative as a statement of current thinking, but not binding, and not the last word [s1].

Sources

• [s1] Robotically-Assisted Surgical Devices—Premarket Submissions; Draft Guidance for Industry and Food and Drug Administration Staff; Availability — Food and Drug Administration / Federal Register, 25 September 2026.
• [s2] Docket FDA-2026-N-9505, Robotically-Assisted Surgical Devices—Premarket Submissions (draft guidance document GUI01500081) — U.S. Food and Drug Administration (Regulations.gov).